Multifunctional block copolymer micelles for the delivery of 111in to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 177-186

  Fonge, Humphrey ^a   Lee, Helen ^a   Reilly, Raymond M ^a,b,c   Allen, Christine ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

111In; Auger electron radiotherapy; Block copolymer micelle; Breast cancer; Epidermal growth factor receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; MACROGOL; PENTETATE INDIUM IN 111; POLYCAPROLACTONE;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; MICELLE; NUCLEAR IMPORT; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR BINDING; TRANSMISSION ELECTRON MICROSCOPY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ELECTRONS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MICELLES; PENTETIC ACID; POLYMERS; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR STEM CELL ASSAY;

EID: 76249103637     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900201v     Document Type: Article

References (50)

1. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr.-Relat. Cancer 2001, 8, 3-9.
2. Rampaul, R. S.; Pinder, S. E.; Nicholson, R. I.; Gullick, W. J.; Robertson, J. F.; Ellis, I. O. Clinical value of epidermal growth factor receptor expression in primary breast cancer. In. Adv. Anat. Pathol. 2005, 12, 271-273.
3. Herbst, R. S.; Langer, C. J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 2002, 29, 27-36.
4. Neal, D. E.; Marsh, C.; Bennett, M. K.; Abel, P. D.; Hall, R. R.; Sainsbury, J. R.; Harris, A. L. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985, 1, 366-368.
5. Fyles, A. W.; McCready, D. R.; Manchul, L. A.; Trudeau, M. E.; Merante, P.; Pintilie, M.; Weir, L. M.; Olivotto, I. A. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N. Engl. J. Med. 2004, 351, 963-970.
6. Tokuda, Y. Antibodies as molecular target-based therapy: trastuzumab. Int. J. Clin. Oncol. 2003, 8, 224-229.
7. Nicholson, R. I.; Gee, J. M. Oestrogen and growth factor crosstalk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer 2000, 82, 501-513.
8. Klijn, J. G.; Berns, P. M.; Schmitz, P. I.; Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992, 13, 3-17.
9. Goldenberg, D. M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 2002, 43, 693-713.
10. Goldenberg, D. M.; Sharkey, R. M. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q. J. Nucl. Med. Mol. Imaging 2006, 50, 248-264.
11. Buchegger, F.; Perillo-Adamer, F.; Dupertuis, Y. M.; Delaloye, A. B. Auger radiation targeted into DNA: a therapy perspective. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 1352-1363.
12. Bailey, K. E.; Costantini, D. L.; Cai, Z.; Scollard, D. A.; Chen, Z.; Reilly, R. M.; Vallis, K. A. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. J. Nucl. Med. 2007, 48, 1562-1570.
13. Cai, Z.; Chen, Z.; Bailey, K. E.; Scollard, D. A.; Reilly, R. M.; Vallis, K. A. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J. Nucl. Med. 2008, 49, 1353-1361.
14. Chen, P.; Cameron, R.; Wang, J.; Vallis, K. A.; Reilly, R. M. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J. Nucl. Med. 2003, 44, 1469-1478.
15. Reilly, R. M.; Chen, P.; Wang, J.; Scollard, D.; Cameron, R.; Vallis, K. A. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J. Nucl. Med. 2006, 47, 1023-1031.
16. Danson, S.; Ferry, D.; Alakhov, V.; Margison, J.; Kerr, D.; Jowle, D.; Brampton, M.; Halbert, G.; Ranson, M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 2004, 90, 2085-2091.
17. Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K.; Shimada, Y.; Nakahama, H.; Matsumura, Y. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer 2007, 97, 170-176.
18. Negishi, T.; Koizumi, F.; Uchino, H.; Kuroda, J.; Kawaguchi, T.; Naito, S.; Matsumura, Y. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br. J. Cancer 2006, 95, 601-606.
19. Adams, M. L.; Lavasanifar, A.; Kwon, G. S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92, 1343-1355.
20. Xiong, M. P.; Yanez, J. A.; Remsberg, C. M.; Ohgami, Y.; Kwon, G. S.; Davies, N. M.; Forrest, M. L. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J. Controlled Release 2008, 129, 33-40.
21. Hamaguchi, T.; Matsumura, Y.; Suzuki, M.; Shimizu, K.; Goda, R.; Nakamura, I.; Nakatomi, I.; Yokoyama, M.; Kataoka, K.; Kakizoe, T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 2005, 92, 1240-1246.
22. Shokeen, M.; Fettig, N. M.; Rossin, R. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles. Q. J. Nucl. Med. Mol. Imaging 2008, 52, 267-277.
23. Hoang, B.; Lee, H.; Reilly, R.; Allen, C. Non-Invasive Monitoring of the Fate of 111In-Labeled Block Copolymer Micelles by High Resolution and High Sensitivity MicroSPECT/CT Imaging. Mol. Pharmaceutics 2009, 6, 581-592.
24. Rossin, R.; Pan, D.; Qi, K.; Turner, J. L.; Sun, X.; Wooley, K. L.; Welch, M. J. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J. Nucl. Med. 2005, 46, 1210-1218.
25. Xiong, X. B.; Mahmud, A.; Uludag, H.; Lavasanifar, A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm. Res. 2008, 25, 2555-2566.
26. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release 2001, 74, 47-61.
27. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 2000, 65, 271-284.
28. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47, 3039-3051.
29. Kataoka, K.; Matsumoto, T.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Fukushima, S.; Okamoto, K.; Kwon, G. S. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Controlled Release 2000, 64, 143-153.
30. Lee, H.; Hu, M.; Reilly, R. M.; Allen, C. Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol. Pharmaceutics 2007, 4, 769-781.
31. Torchilin, V. P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9, E128-147.
32. Zeng, F.; Lee, H.; Allen, C. Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjugate Chem. 2006, 17, 399-409
33. Zeng, F.; Allen, C. Synthesis of carboxy-functionalized heterobifunctional poly(ethylene glycol) by a thiol-anionic polymerization method. Macromolecules 2006, 39, 6391-6398.
34. Zhang, X.; Jackson, J. K.; Burt, H. M. Determination of surfactant critical micelle concentration by a novel fluorescence depolarization technique. J. Biochem. Biophys. Methods 1996, 31, 145-150.
35. Liu, J.; Lee, H.; Allen, C. Formulation of drugs in block copolymer micelles: drug loading and release. Curr. Pharm. Des. 2006, 12, 4685-4701.
36. Reilly, R. M.; Scollard, D. A.; Wang, J.; Mondal, H.; Chen, P.; Henderson, L. A.; Bowen, B. M.; Vallis, K. A. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. J. Nucl. Med. 2004, 45, 701-708.
37. Hu, M.; Chen, P.; Wang, J.; Chan, C.; Scollard, D. A.; Reilly, R. M. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 301-310.
38. Franken, N. A.; Rodermond, H. M.; Stap, J.; Haveman, J.; van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1, 2315-2319.
39. Allen, C.; Maysinger, D.; Eisenberg, A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf., B 1999, 16, 3-27.
40. Blanco, E.; Kessinger, C. W.; Sumer, B. D.; Gao, J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. (Maywood) 2009, 234, 123-131.
41. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65, 11631-11638.
42. Mikhail, A. S.; Allen, C. Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels. J. Controlled Release, in press.
43. Dreher, M. R.; Liu, W.; Michelich, C. R.; Dewhirst, M. W.; Yuan, F.; Chilkoti, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98, 335-344.
44. Allen, C.; Yu, Y.; Eisenberg, A.; Maysinger, D. Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles. Biochim. Biophys. Acta 1999, 1421, 32-38.
45. Maysinger, D.; Berezovska, O.; Savic, R.; Soo, P. L.; Eisenberg, A. Block copolymers modify the internalization of micelle-incorporated probes into neural cells. Biochim. Biophys. Acta 2001, 1539, 205-217.
46. Mamot, C.; Drummond, D. C.; Greiser, U.; Hong, K.; Kirpotin, D. B.; Marks, J. D.; Park, J. W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003, 63, 3154-3161.
47. Reilly, R. M.; Kiarash, R.; Cameron, R. G.; Porlier, N.; Sandhu, J.; Hill, R. P.; Vallis, K.; Hendler, A.; Gariepy, J. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J. Nucl. Med. 2000, 41, 429-438.
48. Goddu, S. M.; Howell, R. W.; Rao, D. V. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. Nucl. Med. 1994, 35, 303-316.
49. Luo, L.; Tam, J.; Maysinger, D.; Eisenberg, A. Cellular internalization of poly(ethylene oxide)-b-poly(epsilon-caprolactone) diblock copolymer micelles. Bioconjugate Chem. 2002, 13, 1259-1265.
50. Chen, P.; Mrkobrada, M.; Vallis, K. A.; Cameron, R.; Sandhu, J.; Hendler, A.; Reilly, R. M. Comparative antiproliferative effects of 111In-DTPA-hEGF, chemotherapeutic agents and gammaradiation on EGFR-positive breast cancer cells. Nucl. Med. Biol. 2002, 29, 693-639.